Results 31 to 40 of about 53,085 (229)

Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types

open access: yesJournal of Experimental & Clinical Cancer Research, 2010
Background Survivin is known playing a role in drug resistance. However, its role in bortezomib-mediated inhibition of growth and induction of apoptosis is unclear.
Chanan-Khan Asher A   +4 more
doaj   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Carfilzomib preserves dendritic cell phenotype and function compared with bortezomib [PDF]

open access: goldFront Immunol
Wang L   +6 more
europepmc   +3 more sources

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

open access: yesFEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo   +6 more
wiley   +1 more source

Precision Matters: Minor Concentration Deviations of DMSO May Cause Major Efficacy Shifts

open access: yesAngewandte Chemie, EarlyView.
Low‐concentration dimethyl sulfoxide (DMSO) has long been regarded as biologically safe in drug discovery. However, increasing DMSO from 0.1% to 0.9% reduces photosensitizer PNA‐9 particle size from 657 nm to 260 nm, enhancing endocytosis and photodynamic therapy outcomes.
Sisi Yuan   +6 more
wiley   +2 more sources

Proteasome Inhibitor Bortezomib Suppresses Nuclear Factor-Kappa B Activation and Ameliorates Eye Inflammation in Experimental Autoimmune Uveitis

open access: yesMediators of Inflammation, 2015
Bortezomib is a proteasome inhibitor used for hematologic cancer treatment. Since it can suppress NF-κB activation, which is critical for the inflammatory process, bortezomib has been found to possess anti-inflammatory activity.
Sheng-Min Hsu   +5 more
doaj   +1 more source

IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis

open access: yesAdvanced Science, EarlyView.
The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui   +12 more
wiley   +1 more source

Downsizing Electrophilic MAX‐Derived Helical Zipper Peptides to Covalently Bind and Degrade Oncogenic MYC

open access: yesAngewandte Chemie, EarlyView.
Oncogenic MYC is a transcription factor that is difficult to inhibit. However, precise positioning of an acrylamide electrophile in MAX to covalently bond to the unique Cys438 in MYC, enabled shortening and optimizing of MAX‐derived, helix‐constrained peptides with high‐affinity and selectivity.
Aline Dantas de Araujo   +7 more
wiley   +2 more sources

Carrier‐Free Berberine/Nitidine Chloride Self‐Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma

open access: yesAdvanced Science, EarlyView.
A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Yiwen Lv   +16 more
wiley   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

open access: yesAngewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma   +5 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy